Tube angiogenic assay indicated that an antiangiogenic drug: bevacizumab, a VEGF‐specific inhibitor, could enhance its antiangiogenic capability, when used in combination with anti‐L1 neutralizing monoclonal antibody (anti‐L1), or in L1‐inhibited glioma cell lines (shL1; Fig. 8A). The gene discussed is VEGFA; the disease is central nervous system cancer.